Dizziness | Jotup

Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

Retrieved on:

Tuesday, August 10, 2021

Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University (DOI: https://doi.org/10.1007/s40122-021-00299-0).

Key Points:

Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University (DOI: https://doi.org/10.1007/s40122-021-00299-0).
IV opioids continue to play a key role in post-operative pain management in my practice.
These findings provide useful insight into the benefit-risk profile of OLINVYK and suggest that it can provide morphine-level pain relief with a lower risk of adverse events.
The findings from this analysis are compelling and suggest that OLINVYK may offer an improved benefit / risk profile for patients requiring IV opioids, said Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena.

Stay Hydrated in Summer Heat

Retrieved on:

Monday, August 9, 2021

As the dog days of summer set in and high temperatures are forecasted in the 90s across much of the Commonwealth this week, Pennsylvania American Water reminds customers to stay healthy and hydrated.

Key Points:

As the dog days of summer set in and high temperatures are forecasted in the 90s across much of the Commonwealth this week, Pennsylvania American Water reminds customers to stay healthy and hydrated.
Safety is one of our top priorities at Pennsylvania American Water, and dehydration is a serious safety concern for employees and customers alike in this summer heat, said Mike Doran, president, Pennsylvania American Water.
We hope these tips will help our customers develop good hydration habits and avoid the dangers of dehydration this summer.
For more hydration tips, watch the companys Summer Hydration Index video and follow Pennsylvania American Water on Facebook , Twitter and Instagram .

Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care

Retrieved on:

Monday, August 9, 2021

Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Infection, AbbVie, RO, Weight loss, Patient, Fatigue, Vincristine, Rash, Hoffmann-La Roche, Pharmacokinetics, Muscle weakness, Confusion, Liver, ROG, Progression-free survival, Chills, Skin, Pain, Phase, Lists of diseases, Dizziness, B-cell lymphoma, Tumor lysis syndrome, Nausea, Abdomen, Prednisone, Risk, CD79B, ADC, Diarrhea, NHL, Survival, Lymphoma, Salvage therapy, Urination, Oxaliplatin, Standard of care, Doxorubicin, Safety, Vomiting, Pain scale, Cyclophosphamide, Cough, Fever, Mark (given name), Walking, Fine chemical, Pharmaceutical industry, Medical device, the POLARIX study, Polivy® (polatuzumab vedotin-piiq), DLBCL, Genentech in Hematology, Genentech, THE POLARIX STUDY, POLIVY® (POLATUZUMAB VEDOTIN-PIIQ), DLBCL, GENENTECH IN HEMATOLOGY, GENENTECH

Genentech would like to thank all investigators, academic partners and people with DLBCL who participated in the study.

Key Points:

Genentech would like to thank all investigators, academic partners and people with DLBCL who participated in the study.
The primary outcome measure is progression-free survival as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma.
POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC).
DLBCL is the most common form of non-Hodgkins lymphoma (NHL), accounting for about one in three cases of NHL.

FDA Approves New Treatment for Pompe Disease

Retrieved on:

Friday, August 6, 2021

Smokeless tobacco, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Fatigue, Lists of diseases, Cell, Genzyme, Food, Dizziness, Safety, Public health, Nausea, Glycogen, Itch, Vaccine, Arthralgia, Degenerative disease, Pediatrics, Patient, Center, Disease, Diarrhea, Center for Drug Evaluation and Research, Needle, Vomiting, Priority review, Thermoregulation, Heart failure, Myalgia, Erythema, Multimedia, FDA, Research, Reproductive medicine, Breathe Me, Paresthesia, Chills, Dietary supplement, Fast Track, Risk, Hives, Cosmetics, Enzyme replacement therapy, China Biologic Products, Death, Glycogen storage disease type II, Anaphylaxis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Headache, Animal, Muscle weakness, Volume overload, Pharmaceutical industry

Patients with Pompe disease have an enzyme deficiency that leads to the accumulation of a complex sugar, called glycogen, in skeletal and heart muscles, which cause muscle weakness and premature death from respiratory or heart failure.

Key Points:

Patients with Pompe disease have an enzyme deficiency that leads to the accumulation of a complex sugar, called glycogen, in skeletal and heart muscles, which cause muscle weakness and premature death from respiratory or heart failure.
"Pompe disease is a rare genetic disease that causes premature death and has a debilitating effect on people's lives," said Janet Maynard, M.D., deputy director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA's Center for Drug Evaluation and Research.
"Today's approval brings patients with Pompe disease another enzyme replacement therapy option for this rare disease.The FDA will continue to work with stakeholders to advance the development of additional new, effective and safe therapies for rare diseases, including Pompe disease."
The effectiveness of Nexviazyme for the treatment of Pompe disease was demonstrated in a study of 100 patients who were randomized to take Nexviazyme or another FDA-approved enzyme replacement therapy for Pompe disease.

Hikma announces US launch of KLOXXADO™ (naloxone HCl) nasal spray 8mg

Retrieved on:

Wednesday, August 4, 2021

Drugs, Morphinans, Opioid antagonists, Tertiary alcohols, Medicine, Chemistry, Dizziness, Naloxone

For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.

Key Points:

For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
In two pharmacokinetic studies, a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO, one spray in one nostril.
The following adverse reactions were reported in two subjects each: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope.

2021 Pipeline Insights on Vestibular Schwannoma - Featuring AstraZeneca, Recursion Pharmaceuticals and Takeda Among Others - ResearchAndMarkets.com

Retrieved on:

Thursday, February 4, 2021

Health, Biotechnology, Nervous system, Neurological disorders, Organ systems, Audiology, Occupational safety and health, Branches of biology, Otorhinolaryngology, Vestibular schwannoma, Tinnitus, Balance disorder, Dizziness, Schwannoma

The "Vestibular Schwannoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Vestibular Schwannoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vestibular Schwannoma pipeline landscape.
Unilateral/asymmetric hearing loss and/or tinnitus and loss of balance/dizziness are early signs of a vestibular schwannoma.
Vestibular Schwannoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Education Resources, Inc. Announces New, Enhanced Online Continuing Education Courses for Therapists

Retrieved on:

Thursday, January 7, 2021

Neurological disorders, Vestibular rehabilitation, Vestibular system, Benign paroxysmal positional vertigo, Dizziness

Newly revised "Advanced Vestibular Rehabilitation Online" teaches the latest rehabilitative procedures and evidence-based treatments and methods for assessing advanced BPPV, cervicogenic dizziness, post-concussion syndrome, and more.

Key Points:

Newly revised "Advanced Vestibular Rehabilitation Online" teaches the latest rehabilitative procedures and evidence-based treatments and methods for assessing advanced BPPV, cervicogenic dizziness, post-concussion syndrome, and more.
Participants can register for "Advanced Vestibular Rehabilitation Online" and the "Toe Walking: Part A & B - Comprehensive Series," at www.educationresourcesinc.com .
Education Resources, Inc. (ERI) is an accredited provider of continuing education for PTs, OTs, and SLPs.
Founded in 1985 by therapists Barbara Goldfarb and Carol Loria, ERI's mission is to provide continuing education that makes a difference for therapists and patients.

Athletico Physical Therapy Opens in Chicago

Retrieved on:

Tuesday, February 18, 2020

Health, Medical specialties, Medicine, Manual therapy, Physical exercise, Physical therapy, Sports medicine, Therapy, Dizziness, Vestibular rehabilitation

CHICAGO, Feb. 18, 2020 /PRNewswire/ --Athletico Physical Therapy has opened a new location in Chicago on Monday, February 17th and is conveniently located just across the street from Mather High School in the Rogers Park - West Ridge community.

Key Points:

CHICAGO, Feb. 18, 2020 /PRNewswire/ --Athletico Physical Therapy has opened a new location in Chicago on Monday, February 17th and is conveniently located just across the street from Mather High School in the Rogers Park - West Ridge community.
Services available at Athletico Rogers Park - West Ridge include:
Physical therapy Our physical therapists treat you to reduce pain, improve or restore mobility, and to help you remain at your optimal health without further risk of injury.
We also offer joint replacement therapy, headache treatment, concussion therapy and more.
If you experience dizziness or other balance issues, take our Vestibular Quiz to find out if your symptoms can be treated with physical therapy.

The Plug Launches All-Natural Herbal Anti-Hangover Supplement

Retrieved on:

Thursday, October 17, 2019

Psychoactive drugs, Drinking culture, Medicine, Organ systems, GABAA receptor positive allosteric modulators, Alcohol abuse, Hangover, Headaches, Alcoholic drink, Dizziness, Nausea

The Plug differentiates itself from market competitors in its all-natural proprietary formula with zero added sugar and an exceptional flavor profile all at only 40 calories.

Key Points:

The Plug differentiates itself from market competitors in its all-natural proprietary formula with zero added sugar and an exceptional flavor profile all at only 40 calories.
Utilizing South Korea's expansive ecological area, The Plug sources pure bedrock water from the foot of the Unak Mountain in Pocheon.
In clinical research trials, The Plug was shown to significantly reduce specific hangover symptoms including sleepiness, headaches, vomiting, dizziness, and nausea.
For the best results it is recommended to drink The Plug before, during, or within two hours after your last alcoholic beverage.

Three New Audiology Aides to Support Newport Beach Balance and Ear Institute

Retrieved on:

Friday, May 24, 2019

Medical specialties, Health, Neurological disorders, Medicine, Otology, Audiology, Auditory system, Otorhinolaryngology, Balance disorder, Dizziness, Balance

NEWPORT BEACH, Calif., May 24, 2019 /PRNewswire-PRWeb/ -- Newport-Mesa Audiology Balance & Ear Institute (the Institute) has promoted three of its employees to the new position of Audiology Aides Alejandra Montoya, Naomi Vega and Raquel Redjai.

Key Points:

NEWPORT BEACH, Calif., May 24, 2019 /PRNewswire-PRWeb/ -- Newport-Mesa Audiology Balance & Ear Institute (the Institute) has promoted three of its employees to the new position of Audiology Aides Alejandra Montoya, Naomi Vega and Raquel Redjai.
The audiology aides support the clinical team with patient care, allowing the audiologists more time to diagnose and treat balance and amplification patients.
"We are so fortunate to have such knowledgeable and experienced aides who provide such excellent care to our patients," said Dr. Jennifer Grace, Clinical Director, Newport-Mesa Audiology Balance & Ear Institute.
Newport-Mesa Audiology Balance & Ear Institute is one of the country's leading practices for the research, diagnosis and treatment of patients with vestibular dysfunction one of the leading causes of dizziness, vertigo and balance disorders.